Aviva PLC Legend Biotech Corp Transaction History

Aviva PLC

$39.7 Billion
Q1 2025

A detailed history of Aviva PLC transactions in Legend Biotech Corp stock. As of the latest transaction made, Aviva PLC holds 49,149 shares of LEGN stock, worth $1.39 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

49,149

Previous 48,300 1.76%

Holding current value

$1.39 Million

Previous $1.57 Million 6.11%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$31.43 - $39.7 $26,684 - $33,705	849 Added 1.76%	49,149 $1.67 Million
Q4 2024 Feb 13, 2025	BUY	$32.49 - $50.28 $55,233 - $85,476	1,700 Added 3.65%	48,300 $1.57 Million
Q3 2024 Nov 14, 2024	SELL	$43.55 - $59.88 $17,420 - $23,952	-400 Reduced 0.85%	46,600 $2.27 Million
Q1 2024 May 14, 2024	BUY	$55.06 - $69.99 $165,180 - $209,969	3,000 Added 6.82%	47,000 $2.64 Million
Q4 2023 Feb 09, 2024	BUY	$57.25 - $69.74 $463,725 - $564,894	8,100 Added 22.56%	44,000 $2.65 Million
Q2 2023 Aug 10, 2023	BUY	$46.28 - $75.01 $97,188 - $157,521	2,100 Added 6.21%	35,900 $2.48 Million
Q1 2023 May 12, 2023	BUY	$43.42 - $57.37 $217,100 - $286,850	5,000 Added 17.36%	33,800 $1.63 Million
Q4 2022 Feb 09, 2023	BUY	$38.8 - $55.46 $89,240 - $127,558	2,300 Added 8.68%	28,800 $1.44 Million
Q3 2022 Nov 14, 2022	BUY	$38.15 - $57.1 $110,635 - $165,590	2,900 Added 12.29%	26,500 $1.08 Million
Q2 2022 Aug 04, 2022	BUY	$33.54 - $55.0 $114,036 - $187,000	3,400 Added 16.83%	23,600 $1.3 Million
Q1 2022 May 13, 2022	BUY	$31.02 - $48.18 $111,672 - $173,448	3,600 Added 21.69%	20,200 $734,000
Q4 2021 Feb 10, 2022	BUY	$41.14 - $56.98 $682,924 - $945,868	16,600 New	16,600 $774,000

Others Institutions Holding LEGN

# of Institutions

229

Shares Held

74.4M

Call Options Held

247K

Put Options Held

406K

View Full List

About Legend Biotech Corp

Ticker LEGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 167,403,008
Market Cap $4.74B
Description
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...

More about LEGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Aviva PLC, based on Form 13F filings with the SEC.

News

Stay updated on Aviva PLC with notifications on news.

Account